相似文献
1
Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination.
Br J Cancer. 1996 Dec;74(11):1828-33. doi: 10.1038/bjc.1996.638.
2
Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation.
Int J Cancer. 1997 Sep 4;72(5):784-90. doi: 10.1002/(sici)1097-0215(19970904)72:5<784::aid-ijc14>3.0.co;2-9.
3
Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer.
Clin Cancer Res. 2006 Feb 15;12(4):1365-72. doi: 10.1158/1078-0432.CCR-05-1672.
4
Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
Cell Immunol. 1997 Dec 15;182(2):137-51. doi: 10.1006/cimm.1997.1224.
5
Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21.
Eur J Immunol. 1995 Sep;25(9):2588-97. doi: 10.1002/eji.1830250928.
6
[CD4+ T-cell immunity and Ab responses to mutant ras protein in pancreas and colon cancer patients].
Zhonghua Zhong Liu Za Zhi. 1996 May;18(3):173-6.
7
HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
J Mol Med (Berl). 2003 Jan;81(1):43-50. doi: 10.1007/s00109-002-0390-y. Epub 2002 Nov 13.
8
[Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Zhonghua Yi Xue Za Zhi. 2008 Jul 22;88(28):1956-60.
9
Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model.
Hum Gene Ther. 2002 May 1;13(7):815-27. doi: 10.1089/10430340252898993.
10
CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients.
Cancer Res. 1995 Jul 15;55(14):2984-7.
引用本文的文献
1
Neo-antigen specific cancer vaccines for acute lymphoblastic leukemia-challenges, opportunities, and future directions.
Cancer Immunol Immunother. 2025 Jun 23;74(8):248. doi: 10.1007/s00262-025-04107-y.
2
In silico prediction of tumor antigens derived from functional missense mutations of the cancer gene census.
Oncoimmunology. 2012 Nov 1;1(8):1281-1289. doi: 10.4161/onci.21511.
3
Trials of gene therapy for pancreatic carcinoma.
Curr Gastroenterol Rep. 2005 Jun;7(3):165-9. doi: 10.1007/s11894-005-0028-7.
4
Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer.
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13255-60. doi: 10.1073/pnas.231326898. Epub 2001 Oct 30.
5
Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumour-reactive T-cells.
Br J Cancer. 2000 Feb;82(3):691-701. doi: 10.1054/bjoc.1999.0982.
6
The potential for gene therapy in pancreatic cancer.
Int J Pancreatol. 1999 Aug;26(1):5-21. doi: 10.1385/IJGC:26:1:5.
本文引用的文献
1
Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study.
Int J Cancer. 1996 Feb 8;65(4):450-3. doi: 10.1002/(SICI)1097-0215(19960208)65:4<450::AID-IJC10>3.0.CO;2-E.
2
T cell clones specific for p21 ras-derived peptides: characterization of their fine specificity and HLA restriction.
Eur J Immunol. 1993 Mar;23(3):754-60. doi: 10.1002/eji.1830230328.
3
Tumor antigens recognized by T lymphocytes.
Annu Rev Immunol. 1994;12:337-65. doi: 10.1146/annurev.iy.12.040194.002005.
4
Binding of ras oncogene peptides to purified HLA-DQ(alpha 1*0102,beta 1*0602) and -DR(alpha,beta 1*0101) molecules.
Scand J Immunol. 1994 Jun;39(6):607-12. doi: 10.1111/j.1365-3083.1994.tb03420.x.
5
p21-ras-peptide-specific T-cell responses in a patient with colorectal cancer. CD4+ and CD8+ T cells recognize a peptide corresponding to a common mutation (13Gly-->Asp).
Int J Cancer. 1994 Jan 2;56(1):40-5. doi: 10.1002/ijc.2910560108.
6
CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-Ras-derived peptide (Gly13-->Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation.
Cancer Immunol Immunother. 1995 Mar;40(3):165-72. doi: 10.1007/BF01517348.
7
Overlapping epitopes encompassing a point mutation (12 Gly-->Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells.
Eur J Immunol. 1993 Oct;23(10):2687-91. doi: 10.1002/eji.1830231045.
8
Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein.
J Exp Med. 1993 May 1;177(5):1493-8. doi: 10.1084/jem.177.5.1493.
9
Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells.
Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):8078-82. doi: 10.1073/pnas.92.17.8078.
10
T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.
Eur J Immunol. 1994 Feb;24(2):410-4. doi: 10.1002/eji.1830240221.
Zotero 插件